The hormonal treatment in prostate cancer

被引：6
作者：
Bastide, C. [1 ]
Bruyere, F. [2 ]
Karsenty, G. [3 ]
Guy, L. [4 ]
Rozet, F. [5 ]
机构：
[1] Aix Marseille Univ, Hop Nord, AP HM, Serv Urol, F-13015 Marseille, France
[2] Univ Tours, CHRU Bretonneau, PRES Ctr Val De Loire Univ, Serv Urol, F-37000 Tours, France
[3] Aix Marseille Univ, Hop Concept, AP HM, Serv Urol & Transplantat Renale, F-13385 Marseille 5, France
[4] Univ Auvergne, Hop G Montpied, Serv Urol, F-63003 Clermont Ferrand 1, France
[5] Inst Mutualiste Montsouris, Serv Urol, F-75014 Paris, France
来源：
PROGRES EN UROLOGIE | 2013年 / 23卷 / 15期
关键词：
Prostate cancer; Hormonal treatment; LHRH analogs; Degarelix; Antiandrogens; Diethylstilbestrol; Estramustin; Abiraterone acetate; Enzalutamid; ANDROGEN DEPRIVATION THERAPY; GROUP PHASE-III; BICALUTAMIDE MONOTHERAPY; CYPROTERONE-ACETATE; INCREASED SURVIVAL; RADIATION-THERAPY; MG MONOTHERAPY; CASTRATION; FLUTAMIDE; TRIAL;
D O I：
10.1016/j.purol.2013.08.325
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Aim. - To describe drugs used in the hormonal treatment (hormonotherapy) of prostate cancer. Material. - Bibliographical search was performed from the database Medline (National Library of Medicine, PubMed) and websites of the HAS and the ANSM. The search was focused on the characteristics, the mode of action, the efficiency and the side effects of the various drugs concerned. Results. - LHRH analogs and the antiandrogens remain the cornerstone in the treatment of locally advanced and metastatic prostate cancer. New therapeutic classes emerged recently (inhibitor of the synthesis of the androgen, the new antiandrogens) and allowed to grow again the limits of the hormone resistance and define the concept castration-resistant prostate cancer. Conclusion -. The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：1246 / 1257
页数：12
相关论文
共 55 条
[21]  
KAISARY AV, 1995, EUR UROL, V28, P215
[22]   The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer [J].
Klotz, Laurence ;
Boccon-Gibod, Laurent ;
Shore, Neal D. ;
Andreou, Cal ;
Persson, Bo-Eric ;
Cantor, Per ;
Jensen, Jens-Kristian ;
Olesen, Tine Kold ;
Schroeder, Fritz H. .
BJU INTERNATIONAL, 2008, 102 (11) :1531-1538
[23]   Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG 9235) [J].
Kucuk, O ;
Fisher, E ;
Moinpour, CM ;
Coleman, D ;
Hussain, MHA ;
Sartor, AO ;
Chatta, GS ;
Lowe, BA ;
Eisenberger, MA ;
Crawford, ED .
UROLOGY, 2001, 58 (01) :53-58
[24]   Secondary hormonal therapy for advanced prostate cancer [J].
Lam, JS ;
Leppert, JT ;
Vemulapalli, SN ;
Shvarts, O ;
Belldegrun, AS .
JOURNAL OF UROLOGY, 2006, 175 (01) :27-34
[25]   FLUTAMIDE VERSUS STILBESTROL IN THE MANAGEMENT OF ADVANCED PROSTATIC-CANCER - A CONTROLLED PROSPECTIVE-STUDY [J].
LUND, F ;
RASMUSSEN, F .
BRITISH JOURNAL OF UROLOGY, 1988, 61 (02) :140-142
[26]   Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide [J].
Mason, M. ;
Maldonado Pijoan, X. ;
Steidle, C. ;
Guerif, S. ;
Wiegel, T. ;
van der Meulen, E. ;
Bergqvist, P. B. F. ;
Khoo, V. .
CLINICAL ONCOLOGY, 2013, 25 (03) :190-196
[27]   Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer [J].
McLeod, DG ;
Iversen, P ;
See, WA ;
Morris, T ;
Armstrong, J ;
Wirth, MP .
BJU INTERNATIONAL, 2006, 97 (02) :247-254
[28]   Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy [J].
Messing, Edward M. ;
Manola, Judith ;
Yao, Jorge ;
Kiernan, Maureen ;
Crawford, David ;
Wilding, George ;
di'SantAgnese, P. Anthony ;
Trump, Donald .
LANCET ONCOLOGY, 2006, 7 (06) :472-479
[29]   Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer [J].
Miyake, H ;
Hara, I ;
Eto, H .
BJU INTERNATIONAL, 2005, 96 (06) :791-795
[30]  
Mongiat-Artus, 2006, PROG UROL S2, V16, P738
123456